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TransfusionSince 1990, several techniques have been developed to photochemically inactivate pathogens in platelet concen-
trates, potentially leading to safer transfusion therapy. The three most common methods are amotosalen/UVA
(INTERCEPT Blood System), riboﬂavin/UVA–UVB (MIRASOL PRT), and UVC (Theraﬂex-UV). We review the
biology of pathogen inactivation methods, present their efﬁcacy in reducing pathogens, discuss their impact on
the functional aspects of treated platelets, and review clinical studies showing the clinical efﬁciency of the
pathogen inactivation methods and their possible toxicity.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Platelets play an essential role in hemostasis; when a transfusion is
necessary, clinicians require platelets of reliable quality to treat their
patients. Advances in surgical techniques and oncological treatments
have led to an ever-increasing need for platelets. On average, an annual
increase of around 10% in the amount of platelets used has been report-
ed in Switzerland since 2000 [1]. In Europe, platelet concentrates (PC)
are obtained either by apheresis (single-donor platelets) or prepared
through buffy-coat extraction from several units ofwhole blood (pooled
platelets). Platelets have to be stored at room temperature (22 °C). Cold
temperatures induce aggregation of von Willebrand factor receptors,
exposing a β-GlcNac residue that leads to capture and elimination of
the platelets by liver macrophages [2,3]. Storage at room temperature
increases the risk of bacterial contamination, assessed as one out of
12,000 PC, which has provided motivation for the development of
pathogen inactivation (PI) methods (although some authors prefer toCI, corrected count increment;
sponse; LTA, light transmission
tivation; RCT, randomized con-
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i.org/10.1016/j.blre.2014.07.0use the term pathogen reduction, we have chosen to use pathogen
inactivation, since it is predominantly used in the literature) [4,5].
More generally, PI methods for blood components are an important
safety issue within the context of globalization and newly emerging
pathogens, not all of which can be detected by current screening
methods [6–8]. This was one of the major points in the Toronto
Consensus Conference recommendation for the implementation of
new technologies [9,10]. Two other possible advantages of PI are the
inactivation of lymphocytes, obviating the need for γ-irradiation
for graft-versus-host disease (GvHD) prophylaxis [11,12], and the
extension of shelf life from 5 to 7 days, allowing for better inventory
management. However, there are still controversies about the position
this type of product holds in the therapeutic arsenal.
2. Pathogen inactivation methods
The INTERCEPT Blood System (Cerus Corporation, Concord CA, USA)
uses a combination of the psoralen amotosalen and UVA light.
Amotosalen penetrates through cellular and nuclear membranes and
establishes a noncovalent link between pyrimidic base residues in
DNA and RNA chains. Exposition to UVA light (320–400 nm) induces a
photochemical reaction that transforms the preexisting link into an
irreversible covalent bond, preventing DNA replication and RNA
transcription. Although all of the toxicological studies of amotosalen
have shown that there is no toxicity at the concentration used [13],
the manufacturer decided that this compound should not be adminis-
tered needlessly to patients. Therefore, this PI method terminates with
a recapture step, during which a compound adsorption device (CAD)the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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between 6 and 16 h and leaves aminimal residual quantity of amotosalen
(b2 μM) [14,15]. Both the spectrum of organisms inactivated by the
INTERCEPT Blood System and the efﬁcacy of this PI method have been
published: there was a 4- to 6-fold log reduction in infectivity for
most pathogens tested [8,16–18]. According to a July 2013 AABB report,
about 20 countries have adopted and are currently using the INTERCEPT
Blood System [19].
MIRASOL PRT (Terumo BCT, Lakewood, CO, USA) uses vitamin
B2 (riboﬂavin) as the photosensitizing agent. After broad-spectrum
UVA/UVB (270–360 nm) illumination of the PC, free oxygen radicals
are formed, causing irreversible damage to guanidic nucleic bases.
Because riboﬂavin is a natural vitamin, the riboﬂavin is not captured
at the end of the procedure [20,21].
Theraﬂex-UV (Macopharma, Tourcoing, France) is still under
development. This method uses UVC, which acts directly on nucleic
acids to induce pyrimidine dimers and block DNA replication [22,23].
All three techniques have also been developed for plasma treatment.
3. Pathogen reduction
The different inactivation methods introduced above have been
tested against varying numbers of pathogens. Both the spectrum of
microorganisms for which documented evidence of inactivation is
available in the scientiﬁc literature and the degree of inactivating
efﬁciency vary among the existing techniques. Results obtained with
one method cannot automatically be transposed to another. Excellent
reviews of the subjects have been published [24–26]. The efﬁcacy of
the three methods on various pathogens is summarized in Table 1. In
general, the available methods are more efﬁcient against enveloped
viruses than against small, nonenveloped viruses. There is more
documented evidence of inactivation with amotosalen/UVA compared
to the competing methods, and the level of log reduction in infectivity
is also generally greater with this method. However, it is important to
consult the available scientiﬁc evidence before drawing conclusions
about the efﬁcacy of a particular method against a speciﬁc pathogen.
Even if there is evidence derived from laboratory studies, epidemiolog-
ical data showing the efﬁcacy of a particular method against a speciﬁcTable 1
Degree of reduction of pathogens in log (adapted from [24] with Permission).
Amotosalen/UVA Riboﬂavin/UV UVC
Enveloped virus
HBV N5.5 2.3 na⁎
HCV N4.5 3.2 na
HIV (cell free) N6.2 N5.9 1.4
HIV (cell-associated) N6.1 N4.5 na
HTLV-I 4.7 na na
CMV (cell-associated) N5.9 na na
West Nile virus N6.0 N5.1 5.4
Chikungunya N6.4 2.1 na
Inﬂuenza A virus N5.9 N5 na
Nonenveloped virus
HAV 0 1.8 na
Parvovirus B19 3.5 to 5.0 N5 5.46
Bacteria
S. aureus ≥6.6 ≥4 N4.8
S. epidermidis ≥6.6 4.2 4.8
P. aeruginosa 4.5 4.6 4.9
E. coli ≥6.4 4.4 N4
Spirochaete bacteria
T. pallidum N6.8 na na
B. burgdorferi N6.8 na na
Parasite
T. cruzi N5.3 6 na
P. falciparum N6 N3.2 na
⁎ Information not available.
Please cite this article as: Kaiser-Guignard J, et al, The clinical and biolo
concentrates, Blood Rev (2014), http://dx.doi.org/10.1016/j.blre.2014.07.0pathogen are the most important type of proof in clinical practice. This
was the case in La Réunion, where a Chikungunya outbreak occurred
[27]. Occasional case reports, even if they appear to provide interesting
epidemiological data, should be interpreted with caution. For example,
a report stated that the INTERCEPT Blood Systemwas apparently inefﬁ-
cient against hepatitis E [28]; however, the company did not claim that
inactivation of this virus was efﬁcient.
4. Functional and biochemical studies
Although PI techniques aim at targeting nucleic acids, it has been
demonstrated that peptides [29] and platelet proteins are also affected
(reviewed elsewhere [30]). The proteomic proﬁle of PI-treated platelets
has been analyzed by several groups, and the results have been summa-
rized: PI had a relatively weak impact on the overall proteome of
platelets, but some data showed that different PI treatments led to an
acceleration of storage lesions. Even though a variety of proteins were
affected (i.e., degraded, oxidized, or phosphorylated), the number of
altered proteins was low (relative to the whole proteome) and the
majority of proteins remained intact. Platelets are anucleated, yet they
contain mRNA and the ribosomal equipment required for de novo
protein synthesis in case of activation [31]. Thus, platelets are capable
of de novo synthesis of proteins, such as of the α2bβ3 integrin [32].
The potential impact of PI techniques targeted toward nucleic acids on
this protein synthesis capacity is largely unknown, as is the relevance
of the protein synthesis capacity for platelet function [33].
Unfortunately, no global test for platelet function is currently
available; however, a number of approaches have been developed
to test platelet function, and some of them are used routinely in the
laboratory to detect functional platelet defects [34–36]. These
techniques have also been used to detect the potential effect of PI on
the metabolic, biochemical, and biological characteristics of platelets.
Basic tests may cover platelet metabolic activity, such as pH, glucose,
and lactate measurements, or lactate dehydrogase (LDH) dosage, plate-
let count, and mean platelet volume (MPV), or they may check for
swirling (a light diffusion phenomenon used to conﬁrm that the discoid
shape of platelets is maintained) [37]. Platelet function tests can be
divided into two categories: tests with and without shear forces. The
former category includes platelet aggregation tests featuring by light
transmission or impedance, ﬂow cytometry, and thromboelastography.
The latter category comprises PFA 100 and Cone and Plate(let) analyzer
(R-Impact) [38]. However, it remains difﬁcult to study platelets in vitro,
given that their manipulation can induce activation [39]. Platelets are
stored in a mixture of plasma and additive solution with citrate as
anticoagulant, which is quite different from their physiological environ-
ment. Certain methods require preliminary reconstitution of whole
blood, or the addition of electrolytes (i.e., Ca++and Mg++) [40,41].
More importantly, in vitro test results are often unable to predict plate-
let function after transfusion, because a certain degree of functional
recovery may occur [42,43]. Finally, study results should be analyzed
while keeping in mind the possible lack of correlation between the
results and clinical efﬁcacy [38,39,43,44].
In 2000, Van Rhenen et al. published the ﬁrst results of a functional
assessment of buffy-coat PCs treated with amotosalen/UVA [45]. Plate-
lets have a predominantly oxidative metabolism and store ATP in their
dense granules. If necessary, they can switch to anaerobic glycolysis
with formation of lactate and H+ ions, leading to a decrease in efﬁcacy
due to lowered pH. In Van Rhenen et al.'s study, the values for pH,
pO2, pCO2, HCO3, glucose, ATP, and lactate were similar to those
observed in untreated platelets after 7 days of storage. Hypotonic
shock response, which allows for the assessment of platelet integrity
and shows decent correlation with platelet function in vivo, was
maintained; this indicates preservation of platelet metabolism [46,47].
However, expression of P-selectin (also known as CD62P), a marker of
platelet activation [48], was increased during storage in PI-treated
platelets, as was the number of lysed platelets visualized by electrongical impact of new pathogen inactivation technologies on platelet
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results regarding platelet metabolism (a greater decrease in pH in the
PI-treated platelets, with increased lactate production and glucose
consumption); however, the values never decreased below the viability
level for platelets (pH b 6.2) during the 7 days of storage [49]. This could
reﬂect a decrease inmitochondrial oxidativemetabolismdue to damage
to mitochondrial nucleic acids, leading to preferential energy produc-
tion through anaerobic glycolysis [50]. These data were conﬁrmed in
studies with apheresis PCs [51–53].
To checkwhether amotosalen/UVA treatment induces apoptosis and
premature platelet lysis, Jansen et al. measured caspase 3 activation
[54]. This enzyme is implicated in a signaling pathway that leads
to platelet apoptosis; its consequence is the expression of phos-
phatidylserine on the membrane surface. Although these markers
increase during storage, no signiﬁcant differences were found in PI-
treated PCs.
In a trial using platelets radiolabeled with indium-111, Snyder et al.
showed a decrease of 7.8% in the recirculation of INTERCEPT-treated
platelets after transfusion in healthy volunteers [55]. The mean survival
of the platelets decreased from 6.0 to 4.8 days. However, these values
are still compatible with an acceptable efﬁcacy and are consistent with
the reduction in recirculation of PI-treated platelets after transfusion
observed in clinical studies.
Compared to untreated platelets, INTERCEPT-treated platelets
express more activation markers on their surface, such as P-selectin
(contained in alpha granules and expressed on the platelet surface
after activation) and CD42b (also known as Gp1b, the linkage site for
thrombin and von Willebrand factor) [56]. Previous studies have
shown that the degree of platelet activation, such as the activation
measured by ﬂow cytometry for speciﬁc markers, could have an impact
on the functional capacity of platelets, leading to a decreased response
in aggregation tests with different agonists [57–59].
To assess the capacity of induction of clot formation in PI-treated
platelets, Tynngard et al. compared amotosalen/UVA-treated platelets
(stored in a mixture of 38% plasma and 62% InterSol) with standard
platelets stored in 100% plasma. Using free oscillation rheometry
(Rheorox, an equivalent of ROTEM), they observed a signiﬁcantly
shorter coagulation time in PI-treated platelets [60].
Lozano et al. showed on rabbit aorta fragments under ﬂow condi-
tions (low shear rates of 800/s) that therewas no difference in adhesion
between amotosalen/UVA-treated and untreated platelets until day 7,
when adhesion of PI-treated platelets was better [61]. Another study
used the Impact-R cone and plate(let) analyzer to compare standard
PCs with amotosalen/UVA- and riboﬂavin/UV-treated platelets under
high shear stress conditions (2000/s) [62]. Adhesion of the untreated
PCs was lower, and during storage, the adhesion of riboﬂavin/UV-
treated plateletswas signiﬁcantly less diminished than that of untreated
or amotosalen/UVA-treated platelets. The correlation of this ﬁnding
with clinical ﬁndings has been documented in several trials [63,64].
The discordance with the results produced by Lozano et al. may be
explained by differences in test conditions. In the same study, in PI-
treated PCs, the authors discovered a storage-induced increase in
the expression of CD41 and CD61 (GPIIb/IIIa, a ﬁbrinogen receptor),
increased expression of P-selectin, and a decrease in the aggregatory
response after stimulation with TRAP6 (an agonist of the thrombin
receptor PAR-1). This decrease was signiﬁcantly lower in riboﬂavin/
UV-treated platelets.
To better assess intrinsic platelet characteristics, Hechler et al.
washed platelets [65] to remove the storage medium. They suspended
the platelets in neutral Tyrode's buffer containing glucose [66]. Expres-
sion of P-selectin and GPIIb/IIIa was notmodiﬁed after amotosalen/UVA
treatment, norwas aggregation after stimulationwith different agonists
(i.e., ADP, collagen, and thrombin). These results differ signiﬁcantly
from previously published data and suggest that the storage medium
may have an inhibitory-yet-reversible effect on platelets. Similarly
their study of mitochondrial transmembrane potential did not showPlease cite this article as: Kaiser-Guignard J, et al, The clinical and biolo
concentrates, Blood Rev (2014), http://dx.doi.org/10.1016/j.blre.2014.07.0any modiﬁcations, indicating that there was no mitochondrial damage.
These ﬁndings were conﬁrmed by another trial on mitochondrial DNA
[50].
In our laboratory, a ﬁbrinogen adhesion test under static conditions
did not detect differences in adhesion between untreated and
amotosalen/UVA-treated platelets (submitted manuscript). However,
after 4–7 days of storage, adhesionwas increased in PI-treated platelets.
These data were supported by increased expression of GPIIb/IIIa, as
measured by PAC-1 levels in PI-treated PCs after 7 days of storage;
this measure was correlated with energy metabolism and membrane
integrity.
In summary, functional and biochemical studies have revealed
that PI has a moderate impact on platelet function, sometimes with
discordant results, illustrating the difﬁculties of assessing platelet
function in vitro. Data suggestive of damage to mitochondrial meta-
bolism have not been clearly conﬁrmed. Storage lesions may be more
pronounced, since increased P-selectin expression and decreased
agonist-induced aggregation was observed [67]. PI-treated platelets
seemingly present a higher basic activation state, with higher surface
expression of GPIIb/IIIa; this could explain the faster clearance, leading
to lower recirculation rates, observed in some clinical trials. The inﬂu-
ence of the storage medium (i.e., plasma, InterSol, or Tyrode buffer) is
obviously substantial and could explain some of the discordant study
results. However, hemostatic function appears to be preserved in PI-
treated PCs compared to standard PCs, under both static and ﬂow
conditions, in concordancewith clinical observations that did not detect
an increase in the bleeding risk.
5. Adverse effects and hemovigilance
Some of the reactions following PC transfusion can be explained by
the presence of cytokines and chemokines that are released during
storage. The occurrence of undesirable reactions has notably been
linked to the presence of sCD40L. According to a study by Cognasse
et al., treatment of PC with amotosalen/UVA does not increase the
production of detrimental cytokines [68].
Published hemovigilance data predominantly concern INTERCEPT.
This technique was approved in France in 2002 (AFSSAPS) and in
Germany (PEI) and Switzerland (Swissmedic) in 2009. Switzerland
was the ﬁrst country to implement INTERCEPT nationwide from 2011.
Swiss hemovigilance data on the transfusion of 551 PCs revealed a
transfusion reaction (TR) rate of 2% and a corrected count increment
(CCI) of 10,000 after 1–4 h [69]. French hemovigilance data showed
no increase in the number of platelet transfusions before and after the
introduction of INTERCEPT and conﬁrmed the decrease in the TR rate
[70]. A decrease in the TR rate linked to the use of additive solutions
has been described previously [71], but the French data appears to
show a speciﬁc PI effect that is independent of plasma substitution. In
Belgium, a retrospective study on transfusion data compared a 3-year
period before and after the introduction of INTERCEPT; there were no
differences in the number of PC transfusions per day of thrombocytope-
nia, in the total dose of platelets administered to patients, or in the
number of red blood cell (RBC) transfusions given to thrombocytopenic
patients [72]. Finally, a prospective hemovigilance program conducted
in France, Belgium, and Spain that included 7437 PC transfusions,
mostly in hemato-oncological patients, revealed an undesirable event
rate of 0.9% after transfusion without any bacterial contamination [73].
These hemovigilance reports all conﬁrm both the safety and efﬁcacy of
INTERCEPT-treated PCs in a huge number of platelet transfusions.
6. Clinical studies
The results of six phase III randomized controlled trials (RCTs) with
INTERCEPT-treated PCs have been published since 2003, as well as one
with MIRASOL-treated PCs [74–79]. All of the studies had at least two
study arms in which one group of patients received PI PCs, while thegical impact of new pathogen inactivation technologies on platelet
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dominantly hemato-oncology patientswhowere receivingprophylactic
transfusion protocols in a setting of post-chemotherapy thrombocyto-
penia; the study periods ranged from 28 to 56 days. One of the principal
stakes of these studies rested on the deﬁnition of the primary outcome.
The more common outcome used was the change in CCI. The CCI
indicates the increase in platelet count after transfusion, corrected for
the number of platelets transfused and the body surface area of the
recipient. This formula was originally used to deﬁne refractory state to
platelet transfusion; as such, it is not an intrinsic quality parameter for
platelet products [80]. CCI has the advantage of easy measurement
and allows for quantitative comparisons. However, it has not been
established that this measure is of clinical relevance. For example, in the
PLADO study, although the CCIs were different in three groups of patients
who received 1.1 × 1011, 2.2 × 1011, and 4.4 × 1011 platelets/m2,
respectively, the clinical outcomes were similar [81].
The SPRINT trial was the only trial to use the bleeding score, as
deﬁned by the World Health Organization (WHO), as the primary
outcome measure [77]. Other clinical criteria, such as the number of PC
and RBC transfusions and the time interval between two transfusions,
have been used as secondary outcomes, together with the TR rate, the
appearance of neoantigens, and the risk of platelet alloimmunization.
In addition to how clinically relevant outcomes are deﬁned, numer-
ous other biases may arise in association with the methods used in the
aforementioned studies. Possible pitfalls were described by Cook and
Heddle in their review of themethodology of clinical trials with patients
transfused with PI-treated PCs [82]. The very characteristics of the PCs
varied among the studies, making it difﬁcult to compare the study
results: platelets were obtained through apheresis or prepared from
buffy coats (in Europe) or platelet-rich plasma (in the USA), the number
of platelets per bag and the composition of the additive solution
differed, the shelf life was variable, and the presence or absence of
γ-irradiation and the transfusion threshold was substantially different
from one study to another. Part of the variability may also be
patient linked, although the exclusion criteria generally contained risk
factors for platelet refractoriness, such as splenomegaly, HLA or HPA
alloimmunization, and the presence of disseminated intravascular
coagulopathy. To avoid the possible impact of a variable number of
transfusions per patient, only the ﬁrst eight transfusions were assessed
in both the euroSPRITE and the MIRACLE study [82]. Interpatient
variability was further complicated by the variability of the response
to transfusions in a single patient; interpretation of a study becomes
more complex when randomization occurs at the patient level and
not at the transfusion level. Lozano et al. limited their assessment to
one transfusion in order to reduce this effect [76]. It is also noteworthy
that only the Janetzko study [74] formally deﬁned the incidence of
bacterial contamination as a secondary outcome, although the frequen-
cy of this complication was at an order of magnitude beyond the
predictive power of these studies.
The ﬁrst RCT of PI-treated PCs, published in 2003, was the
euroSPRITE trial [79], which compared 103 patients who received PC
prepared from buffy coats. The PCs were either treated or untreated
with amotosalen/UVA (311 and 256 transfusions, respectively), and
the transfusion results were monitored over a time period of 56 days.
The CCI was not signiﬁcantly different between the two groups
(13.100± 5.400 vs. 14.900± 6.200, respectively). Secondary outcomes
(i.e., number of platelet transfusions per patient, occurrence of bleeding,
number of RBCs transfused, development of a refractory state, and TR
rate) also did not differ between the two groups.
The SPRINT trial [77] included 645 patients and was published in
2004. The primary outcome was the occurrence of grade 2 bleeding
(WHO classiﬁcation) during a follow-up period of 28 days; platelets
were obtained through apheresis. The occurrence of grade 2 bleeding
in the amotosalen/UVA-treatment arm was 58.5%, versus 57.5% in the
control group. The occurrence of grade 3 or 4 bleeding was 4.1% and
6.1% in the amotosalen/UVA-treated and control groups, respectively.Please cite this article as: Kaiser-Guignard J, et al, The clinical and biolo
concentrates, Blood Rev (2014), http://dx.doi.org/10.1016/j.blre.2014.07.0No statistically signiﬁcant difference was observed. In contrast with
the results of the euroSPRITE trial, CCIs were lower in the recipients of
PI-treated PCs compared to controls (11.1 versus 16.0), and the former
group received more transfusions (8.4 vs. 6.2 per patient). It should,
however, be noted that the platelet content was lower in the treatment
group than in the control group (3.7 × 1011 vs. 4.0 × 1011/unit).
In Janetzko et al.'s study [74], a commercially available kit for
amotosalen/UVA treatment was used, which reduced the number of
preparation steps and limited the platelet loss. Their RCT of 43 patients
revealed a decrease (although not statistically signiﬁcant) in CCI after
the transfusion of apheresis platelets treated with amotosalen/UVA
(11.600 ± 7.300 vs. 15.100 ± 6.400), conﬁrming the results of the
SPRINT trial. However, the standard platelets were stored in 100% plas-
ma, whereas the amotosalen/UVA-treated platelets were resuspended
in a mixture of plasma and platelet additive solution III (PAS III) [74].
Since there was no difference in the number of transfusions or in the
occurrence rate of bleeding and adverse effects, the authors concluded
that both types of PC were equivalent in terms of efﬁcacy and safety.
In contrast with the results of the other studies, theHOVON trial [75]
included three arms: PCs stored in full plasma, in PAS III without
INTERCEPT, and in PAS III with INTERCEPT. Although the primary out-
come of this study was CCI and not bleeding, even prior to publication
major concerns arose about a possible reduction in clinical efﬁcacy for
PCs treated with amotosalen/UVA: 32% of patients in the INTERCEPT
arm presented a bleeding episode compared to 19% in the plasma
arm, and CCIs in the INTERCEPT arm were lower by 31% compared to
the plasma arm. However, this study had serious ﬂaws, including a
lack of blinding, the absence of bleeding assessment by independent
and trained observers, and the use of a bleeding grading system
different from theWHO scale. Furthermore, the only statistically signif-
icant differences were found between the plasma arm and the PAS III
+ INTERCEPT arm, leaving some doubts about the speciﬁc effects of
additive solution and INTERCEPT treatment [83].
One of the advantages of PI-treated PCs is that shelf life can be
extended from 5 to 6 or 7 days, since the 5-day limitation was based
on the risk of bacterial contamination [84]. In the TESSI trial (Efﬁcacy
and Safety Study of Platelets Treated for Pathogen Inactivation and
Stored for Up to Seven Days), Lozano et al. [76] opted for an innovative
study design: they compared the therapeutic efﬁcacy of amotosalen/
UVA-treated vs. standard platelets that had been stored for 6 or
7 days. Every patient was included for only a single transfusion. The
authors conﬁrmed the noninferiority of PCs treated with INTERCEPT
and stored for 6 or 7 days: the mean CCIs (after 1 h) were 8.163 and
9.383, respectively, for amotosalen/UVA-treated and standard platelets.
To minimize confounding variables, a Swiss team from Basel
performed an open prospective study that compared a group of 44
patients who received amotosalen/UVA-treated apheresis platelets
with a group of 72 patientswho receivedγ-irradiated standard platelets
in PAS III over a period of 28 days. The platelet content of the bags was
identical (around 2.8 × 1011/unit) between the two groups. There
was no difference in the CCI (after 1 h) between the two study arms
(11.400 ± 4.900 vs. 11.000 ± 4.900, respectively, for amotosalen/
UVA-treated apheresis platelets and γ-irradiated standard platelets)
[78]. Due to a lack of availability of INTERCEPT-treated PCs, 38% of the
transfusions in the INTERCEPT arm were given with standard platelets.
A per-protocol analysis (including only transfusions with INTERCEPT-
treated platelets) revealed a CCI (after 1 h) of 10.700 ± 5.600.
The MIRACLE study is the only published RCT thus far of PCs treated
with riboﬂavin/UV (MIRASOL). It was published in 2010 and included
118 patients. The CCI (after 1 h) was signiﬁcantly lower in the riboﬂa-
vin/UV arm than in the control arm (11.725 ± 1.14 vs. 16.939 ± 1.15,
respectively). Thus, the study did not meet the previously deﬁned non-
inferiority limit of 30% loss. However, the number of PCs and RBCs
transfused was similar in the two study arms, and the authors raised
the question of whether the CCI is a reliable surrogate marker for
bleeding risk assessment.gical impact of new pathogen inactivation technologies on platelet
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published clinical studies should be interpreted with caution, and
their characteristics and possible biases should be taken into account.
Results obtained with one method cannot be extrapolated to those
obtained by other methods. In the ﬁrst published meta-analysis that
included the HOVON trial, Vamvkas concluded that there was a clinical-
ly signiﬁcant increase in mild and moderate bleeding complications in
the arm receiving treated-platelets [85]. However, this meta-analysis
contained a serious methodological bias: it combined the results of
clinical studies of amotosalem/UVA with the results of a clinical study
of riboﬂavin/broad spectrum UV. In a second meta-analysis, which
was recently published by Cid et al., although the CCIs were lower
after INTERCEPT, the hemostatic efﬁcacy of INTERCEPT-treated PCs
was maintained. These ﬁndings support the results of previously
published hemovigilance data, which did not show an increase in the
number of PC transfusions after INTERCEPT [86].
7. Conclusions
The beneﬁcial effects of INTERCEPT-treated platelets have been
clearly demonstrated. Indeed, they reach beyond the original scope: in
addition to the reduction in infectious risk, INTERCEPT-treated platelets
obviate the need for γ-inactivation for GvHD prophylaxis and extend
the maximum shelf life of platelets from 5 to 7 days. Furthermore, a
reduction in the transfusion reaction rate has been observed, due either
to partial plasma substitution by additive solution or to a speciﬁc PI
effect. Although platelet recovery, as measured by CCI or survival
studies with radiolabeled platelets, is lower after PI treatment, the
hemostatic efﬁcacy, as measured by clinical outcomes, is maintained.
The results of prospective clinical trials have been conﬁrmed by retro-
spective hemovigilance data. However, the heterogeneity of these
clinical trials complicates their comparison.
At the laboratory level, PI-treated platelets seem to present an
increased activation status, and moderate changes at the level of
mitochondrial metabolism are expressed in increased metabolic
parameters; however, the results are discordant among studies.
These modiﬁcations might explain the reduced survival and
decreased recirculation level of PI-treated platelets, although the
increased activation status of PI-treated platelets does not lead to a
decrease in hemostatic efﬁcacy. Activated ﬁbrinogen receptor
expression appears to be increased after PI, perhaps through a direct
effect of PI on this integrin. These data relate mainly to the
amotosalen/UVA technique and, to a lesser extent, to the riboﬂavin/
UV method.
The data available thus far in the literature allow us to conclude that
the hemostatic efﬁcacy of PI-treated platelets is satisfactory. In addition
to a sharp decrease in the transmitted infection risk, PI also provides
GvHD prophylaxis and extension of the maximum platelet shelf life
from 5 to 7 days.
Practice points
• PI represents of an important change of paradigms in transfusion
medicine: testing and exclusion of blood donors according to speciﬁc
risks are not the sole pillars of security of blood transfusion.
• PI methods are particularly efﬁcient to prevent transfusion-related
bacterial infections.
• PI methods of PC globally reduce the risk of transfusion transmitted
diseases and replace γ-irradiation for the prevention of GvHD.
• Hemostatic efﬁcacy of PI-treated PC appears to be maintained,
although the CCI is lower when compared to untreated PC.
Research agenda
• The future of PI in transfusion medicine will be determined according
to the results of well conducted, double blind, clinical trials.Please cite this article as: Kaiser-Guignard J, et al, The clinical and biolo
concentrates, Blood Rev (2014), http://dx.doi.org/10.1016/j.blre.2014.07.0• The storage lesions have to be deciphered according to time of storage
as well as to the particular and speciﬁc PI methods that are used.
• Inactivation of all blood products will be a challenge for the future:
fundamental, translational and clinical studies are needed to better
characterize the molecular mechanisms involved by PI methods.
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